Elshof et al. (2018) conducted a 10-year study of 9799 women treated for ductal carcinoma in situ. They found the incidence of invasive breast cancer and mortality rates of the women with DCIS were analyzed with comparisons of the following:
• breast-conserving surgery (BCS) alone.
• breast-conserving surgery (BCS) plus radiotherapy
• mastectomy
Incidence of invasive cancer
| BCS alone | BCS with R.T. | Mastectomy | |
| Yes | 412 (16.1) | 219 (8.5) | 295 (6.3) |
| No | 2146 (83.9) | 2355 (91.5) | 4372 (93.7) |
Mortality results
According to Elshof et al. (2018), breast cancer mortality 10 years after DCIS of 9799 women was 2.3% for women <50 years and 1.4% for women >50 years treated for DCIS.
Hanna et al., (2019) found recurrence of DCIS to have an overall mortality rate of 3.3%
Also, women diagnosed with primary DCIS had a higher risk of dying from breast cancer than women in the general population.
Some of the lower mortality results from invasive cancer are attributed to the follow-up care done to DCIS patients after surgery.
Prognosis with LCIS
In a 9-year study of 16,00 women with LCIS (Cheng et al. 2017) the following survival outcomes were reported:
Wong et al. (2017) analyzed the outcomes of 19,462 women with LCIS over 10 and 20-year intervals who developed primary breast cancer. 1837 of these women (9.4%) developed primary breast cancer. 55% of the breast cancer occurred in the same breast as the LCIS. These researchers (2017) also found that most of these breast cancers were of low/intermediate grade, hormone receptor-positive, and diagnosed early. The researchers found the type of surgical treatment for LCIS did not affect long-term survival. The 10- and 20-year survival with LCIS was 98.9 and 96.3%, respectively.
Instant Feedback:
Breast cancer mortality 10 years after DCIS of 9799 women was 2.3% for women <50 years and 1.4% for women >50 years treated for DCIS.
Cheng, P., Huang, P., Shou, J., Hu, G., Han, M. & Huang, J. (2017). Treatment and survival outcomes of lobular carcinoma in situ of the breast: a SEER population-based study. Oncotarget. 8(61), 103047–103054.
Elshof, L. E., Schmidt, M. K., Rutgers, E., van Leeuwen, F. E., Wesseling, J., & Schaapveld, M. (2018). Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ. Annals of Surgery, 267(5), 952–958.
Hanna, W.M., Parra-Herran, C., Lu, FI. et al. (2019). Ductal carcinoma in situ of the breast: An update for the pathologist in the era of individualized risk assessment and tailored therapies. Mod Pathol 32, 896–915.
Wong, S.M., King, T., Boileau, J.F., Barry, W.T. & Golshan, M. (2017). Population-Based Analysis of Breast Cancer Incidence and Survival Outcomes in Women Diagnosed with Lobular Carcinoma In Situ. Ann Surg Oncol. 24(9), 2509-2517.
© RnCeus.com